FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W177063975> ?p ?o ?g. }

• W177063975 abstract "Recombinant human deoxyribonuclease is currently used to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis.To determine whether the use of recombinant human deoxyribonuclease in cystic fibrosis is associated with improved mortality and morbidity as compared to placebo and to identify any adverse events associated with its use. To compare the efficacy of recombinant human deoxyribonuclease with other mucolytics.The Cochrane Cystic Fibrosis and Genetic Disorders Group specialist trials register which comprises references identified from comprehensive electronic database searches, hand searching relevant journals and abstracts from conferences. The company producing recombinant human deoxyribonuclease was also contacted. Date of the most recent search of the Group's specialised register: November 1999.All randomised and quasi-randomised trials where recombinant human deoxyribonuclease was compared to either placebo, standard therapy or another mucolytic for any duration, dose regimen and age of patient with cystic fibrosis of any disease severity.Trials were independently assessed for inclusion criteria, methodological quality and data extraction by the two reviewers. Comparisons were between recombinant human deoxyribonuclease and placebo and recombinant human deoxyribonuclease and other mucolytics. The following outcomes were recorded: Mean % change from baseline in forced vital capacity (FVC), forced expiratory voloume at one second (FEV1) and weight, mean number of respiratory tract exacerbations, days intravenous and oral antibiotics used, mean number of days as inpatient, number of deaths, adverse events and the cost of therapy.Seven primary clinical trials were identified, totalling 1710 patients. Two further studies examined the health care cost of patients from one of the clinical trials. No eligible studies compared recombinant human deoxyribonuclease to another mucolytic. Five trials presented outcomes at up to one month, one at three months and one at six months. No reduction in mortality for treated patients was identified (Relative Risk (RR) at six month 1.01, 95%Confidence Interval (CI) 0.09, 11.11). Lung function improved to a greater extent in the treated groups (at six months Weighted Mean Difference (WMD) FEV1 5.7, 95%CI 4.18, 7.23, at three months 7.3, 95%CI 4.04, 10.65). Pooled data from the five trials of up to one month gave WMD 9.2 95%CI 0.93, 17. 6 although there was significant heterogeneity). Recombinant human deoxyribonuclease was well tolerated with no excess of serious adverse events (RR haemoptysis 0.89, 95%CI 0.54, 1.45, pneumothorax 0.97 95%CI 0.19, 4.96). Voice alteration was, however, reported more frequently in the treated groups (RR 2.33 95%CI 1.38, 3.93). No study analysed our pre-defined outcome measure for respiratory exacerbations and insufficient data was available to analyse differences in antibiotic treatment, inpatient stay and quality of life.Studies are of insufficient duration to identify a reduction in mortality or number of respiratory exacerbations. Further trials are required to answer these important questions. Recombinant human deoxyribonuclease therapy is associated with an improvement in lung function after six months treatment, but it is not possible to assess whether this effect on lung function is sustained in the long-term. No studies were identified that compared recombinant human deoxyribonuclease to another mucolytic." @default.
• W177063975 created "2016-06-24" @default.
• W177063975 creator A5005129884 @default.
• W177063975 creator A5053839366 @default.
• W177063975 creator A5058282675 @default.
• W177063975 date "2003-07-21" @default.
• W177063975 modified "2023-10-13" @default.
• W177063975 title "Dornase alfa for cystic fibrosis" @default.
• W177063975 cites W175998601 @default.
• W177063975 cites W1872952081 @default.
• W177063975 cites W1968152866 @default.
• W177063975 cites W1970431627 @default.
• W177063975 cites W1975609078 @default.
• W177063975 cites W1976867283 @default.
• W177063975 cites W1978271506 @default.
• W177063975 cites W1991045784 @default.
• W177063975 cites W1997567908 @default.
• W177063975 cites W2006292526 @default.
• W177063975 cites W2006752980 @default.
• W177063975 cites W2010678373 @default.
• W177063975 cites W2023546954 @default.
• W177063975 cites W2031789064 @default.
• W177063975 cites W2036001221 @default.
• W177063975 cites W2039548615 @default.
• W177063975 cites W2041807185 @default.
• W177063975 cites W2045572299 @default.
• W177063975 cites W2056935354 @default.
• W177063975 cites W2057510647 @default.
• W177063975 cites W2061434168 @default.
• W177063975 cites W2064024196 @default.
• W177063975 cites W2070419306 @default.
• W177063975 cites W2107884278 @default.
• W177063975 cites W2110528741 @default.
• W177063975 cites W2112485011 @default.
• W177063975 cites W2125435699 @default.
• W177063975 cites W2127136998 @default.
• W177063975 cites W2128817585 @default.
• W177063975 cites W2129637598 @default.
• W177063975 cites W2129756193 @default.
• W177063975 cites W2129772791 @default.
• W177063975 cites W2130235475 @default.
• W177063975 cites W2133673354 @default.
• W177063975 cites W2136652636 @default.
• W177063975 cites W2144145895 @default.
• W177063975 cites W2145410540 @default.
• W177063975 cites W2148217897 @default.
• W177063975 cites W2150399236 @default.
• W177063975 cites W2153943794 @default.
• W177063975 cites W2158898740 @default.
• W177063975 cites W2165031309 @default.
• W177063975 cites W2172138333 @default.
• W177063975 cites W2333398204 @default.
• W177063975 cites W2336714143 @default.
• W177063975 cites W4214559180 @default.
• W177063975 cites W4239274289 @default.
• W177063975 doi "https://doi.org/10.1002/14651858.cd001127" @default.
• W177063975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12917899" @default.
• W177063975 hasPublicationYear "2003" @default.
• W177063975 type Work @default.
• W177063975 sameAs 177063975 @default.
• W177063975 citedByCount "47" @default.
• W177063975 countsByYear W1770639752012 @default.
• W177063975 countsByYear W1770639752013 @default.
• W177063975 countsByYear W1770639752014 @default.
• W177063975 countsByYear W1770639752015 @default.
• W177063975 countsByYear W1770639752016 @default.
• W177063975 countsByYear W1770639752017 @default.
• W177063975 countsByYear W1770639752018 @default.
• W177063975 countsByYear W1770639752021 @default.
• W177063975 countsByYear W1770639752022 @default.
• W177063975 countsByYear W1770639752023 @default.
• W177063975 crossrefType "reference-entry" @default.
• W177063975 hasAuthorship W177063975A5005129884 @default.
• W177063975 hasAuthorship W177063975A5053839366 @default.
• W177063975 hasAuthorship W177063975A5058282675 @default.
• W177063975 hasConcept C104317684 @default.
• W177063975 hasConcept C126322002 @default.
• W177063975 hasConcept C142724271 @default.
• W177063975 hasConcept C177713679 @default.
• W177063975 hasConcept C185592680 @default.
• W177063975 hasConcept C197934379 @default.
• W177063975 hasConcept C204787440 @default.
• W177063975 hasConcept C27081682 @default.
• W177063975 hasConcept C2776938444 @default.
• W177063975 hasConcept C2778659741 @default.
• W177063975 hasConcept C40767141 @default.
• W177063975 hasConcept C535046627 @default.
• W177063975 hasConcept C54355233 @default.
• W177063975 hasConcept C552990157 @default.
• W177063975 hasConcept C55493867 @default.
• W177063975 hasConcept C71924100 @default.
• W177063975 hasConcept C86803240 @default.
• W177063975 hasConceptScore W177063975C104317684 @default.
• W177063975 hasConceptScore W177063975C126322002 @default.
• W177063975 hasConceptScore W177063975C142724271 @default.
• W177063975 hasConceptScore W177063975C177713679 @default.
• W177063975 hasConceptScore W177063975C185592680 @default.
• W177063975 hasConceptScore W177063975C197934379 @default.
• W177063975 hasConceptScore W177063975C204787440 @default.
• W177063975 hasConceptScore W177063975C27081682 @default.

• next